Scarica l'app Stockscreener
219.88
1.32%
-2.94
Dopo l'orario di chiusura:
219.10
-0.78
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors - Simply Wall Street
How Biogen Inc. (BIIB) Affects Rotational Strategy Timing - Stock Traders Daily
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? - Zacks Investment Research
Biogen stock closes 0.55 percent higher as Q2 growth holds - AD HOC NEWS
Biogen (BIIB) Could Be 4% Undervalued After Strong Earnings And Product News - simplywall.st
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack - Yahoo Finance
Biogen stock slips before the bell after September 24 close - AD HOC NEWS
Biogen stock trades near its 52-week high on growth bets - AD HOC NEWS
Biogen stock adds 3.40 percent ahead of the open - AD HOC NEWS
Biogen Inc. (BIIB) Options ChainYahoo Finance - Yahoo! Finance Canada
Biogen Inc. stock reaches a new 52-week high - AD HOC NEWS
Biogen stock heads into the open after a 2.7 percent gain - AD HOC NEWS
Biogen stock hits 52-week high at 225.88 USD By Investing.com - Investing.com Australia
Biogen stock hits 52-week high at 225.88 USD - Investing.com
Biogen stock slips after a lower close and analyst notes - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent decline - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Learn Why The Bull Case For Biogen Stock Could Change Following At Home LEQEMBI Approval - simplywall.st
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Zacks Investment Research
Biogen Inc. stock holds near top of 52-week range after EMPAVELI data update - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent slide - ad-hoc-news.de
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Share & Growth Report, 2035 - SNS Insider
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance - AD HOC NEWS
Biogen acquires RayThera Inc. (August 2026) - app.dealroom.co
Biogen Inc. stock gains regulatory boost from Japan approval for Leqembi Pen - AD HOC NEWS
Biogen Inc. stock gains after new EMPAVELI kidney data publication - AD HOC NEWS
Biogen Inc. stock trades near 52-week high as analysts keep a Moderate Buy stance - AD HOC NEWS
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN - Biogen
Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB) - Seeking Alpha
Biogen Announces Published VALIANT Data Showing EMPAVELI Reduced Proteinuria in Adolescents with C3G and Primary IC-MPGN - Quiver Quantitative
Is Biogen Stock Outperforming the S&P 500? - finance.yahoo.com
Eisai and Biogen Announce Japan Approval of LEQEMBI Pen, a Once-Weekly Subcutaneous Alzheimer’s Treatment - Quiver Quantitative
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease - Yahoo Finance
Biogen (BIIB) Wins China Approval For At Home Weekly Alzheimer’s Treatment - simplywall.st
Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 - Biogen
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? - Yahoo Finance
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience - Yahoo Finance
Biogen Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.23% Potential Upside with Strategic Collaborations - DirectorsTalk Interviews
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - TradingView
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):